Canaccord Genuity Maintains Hold on ACADIA Pharmaceuticals, Raises Price Target to $30
Canaccord Genuity analyst Sumant Kulkarni maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Hold and raises the price target from $26 to $30.
55 Biggest Movers From Yesterday
Gainers
Reliance Global Group, Inc. (NASDAQ: RELI) shares jumped 78.7% to close at $5.45 on Tuesday after gaining around 6% on Monday.
What Analysts Have To Say On Acadia’s Narrower Nuplazid Label Expansion Bid
RBC Capital raised the price target on Acadia Pharmaceuticals Inc (NASDAQ: ACAD) to $
The Daily Biotech Pulse: Aldeyra Sinks On Dry Eye Disease Readout, Sanofi Goes Shopping, Regulatory Setback For Aquestive, Aridis Touts Pan-Coronavirus Antibody Cocktail
Here's a roundup of top developments in the biotech space over the last 24 hours:
RBC Capital Maintains Outperform on ACADIA Pharmaceuticals, Raises Price Target to $34
RBC Capital analyst Gregory Renza maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and raises the price target from $32 to $34.
Guggenheim Downgrades ACADIA Pharmaceuticals to Neutral, Announces $28 Price Target
Guggenheim analyst Yatin Suneja downgrades ACADIA Pharmaceuticals (NASDAQ:ACAD) from Buy to Neutral and announces $28 price target.
